. 2021 Feb 4;13(2):516. doi: 10.3390/nu13020516

Table 2.

Summary of the results of the meta-analysis (random effects model).

Cancer Type	Exposure	N° of Studies		RR (95% CI)	I² (%)	Tau²	p within Group ⁺	95% PI
Cancer Type	Exposure	Cohort	Case-Control	RR (95% CI)	I² (%)	Tau²	p within Group ⁺	95% PI
Breast	SSB	4	3	1.14 (1.01−1.30)	0.0	0.0073	0.69	0.88, 1.47
Breast	FJ	3	0	1.13 (0.93−1.38)	0.0	0.0017	0.79	0.52, 2.46
Breast Pre-M	SSB	3	2	1.37 (0.99−1.88)	55.7	0.0358	0.06	0.68, 2.76
Breast Post-M	SSB	4	2	1.18 (0.79−1.75)	54.8	0.1080	0.05	0.43, 3.23
Colorectal	SSB	4	0	1.18 (0.99−1.41)	0.0	0.0039	0.71	0.82, 1.69
Colorectal	FJ	2	2	0.79 (0.16−3.87)	88.5	0.8629	<0.001	0.008, 73.94
Colorectal *	FJ	2	1	1.29 (0.78−2.12)	0.0	0.0120	0.63	0.17, 9.81
Colorectal	SB	0	3	2.02 (0.45−9.01)	62.9	0.2711	0.07	0.00, 5753.1
Colorectal *	SB	0	2	1.57 (0.74−3.35)	0.0	0.0010	0.67	–
Bladder	SB	0	5	1.66 (0.78−3.56)	83.4	0.3226	<0.001	0.22, 12.37
Bladder *	SB	0	4	1.27 (0.85−1.90)	25.3	0.0425	0.26	0.45, 3.60
Prostate	SSB	5	0	1.18 (1.10−1.27)	0.0	0.0012	0.92	1.03, 1.35
Prostate	FJ	4	0	1.03 (1.01−1.05)	0.0	0.0001	0.93	0.98, 1.09
Prostate	SB	1	2	0.97 (0.56−1.69)	2.9	0.0241	0.36	0.07, 12.7
Renal cell	SB	1	2	1.44 (0.46−4.50)	65.4	0.1559	0.056	0.00, 604.16
Pancreatic	SB	4	4	1.28 (0.95−1.72)	58.6	0.0962	0.02	0.56, 2.90
Pancreatic	SSB	4	2	1.01 (0.92−1.11)	0.0	0.0016	0.92	0.87, 1.17
Pancreatic	ASB	3	2	1.07 (0.77−1.48)	43.6	0.0480	0.13	0.48, 2.36

* Results excluding outliers; ⁺ p values of Cochran’s Q-test heterogeneity. ASB: artificial sweetened beverage; FJ: fruit juice; PI: prediction intervals; Post-M: post-menopausal; Pre-M: pre-menopausal; RR: risk ratio; CI: confidence interval; SB: sweetened beverage (including both SSBs and ASBs); SSB: sugar-sweetened beverage.